HALLIE OBRANOVIC: Open Payments
NPI 1710304241 · LOUISVILLE, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,558 in 45 payments from 14 companies in 2025. Trend: 2023 $64 · 2024 $146 · 2025 $1,558
Food & beverage: $1,558
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 7 | $531 |
| AstraZeneca Pharmaceuticals LP | 9 | $266 |
| Genentech, Inc. | 1 | $146 |
| Regeneron Healthcare Solutions, Inc. | 12 | $135 |
| Pharming Healthcare, Inc. | 1 | $125 |
| BioCryst US Sales Co., LLC | 2 | $110 |
| Genentech USA, Inc. | 2 | $43 |
| Novartis Pharmaceuticals Corporation | 2 | $41 |
| CSL Behring | 2 | $39 |
| Lilly USA, LLC | 1 | $33 |
Products named: DUPIXENT, Xolair, TEZSPIRE, ORLADEYO, BREZTRI, Rhapsido, Hizentra, EBGLYSS.
Industry payments across CO — which companies pay providers there.
